RU-2861335-C1 - METHOD FOR STIMULATING REPARATIVE OSTEOGENESIS OF JAW BONES

Abstract

FIELD: medicine; dentistry. SUBSTANCE: invention can be used for stimulating reparative osteogenesis of jaw bones. Method comprises using chondroitin sulphate. One day before dental implantation, 100 mg of chondroitin sulphate is administered intramuscularly to the patient; during the operation, an osteoplastic material impregnated with a chondroitin sulphate solution is introduced into the intraoperative defect. In the postoperative period, the drug chondroitin sulphate is administered intramuscularly according to the scheme: starting from the day of surgery, 3 injections of 100 mg chondroitin sulphate per day, on the fourth day and further 12 injections every other day of 200 mg chondroitin sulphate. EFFECT: increasing the effectiveness of all 4 phases of osseointegration, reducing the likelihood of implant rejection and increasing its osseointegration due to the osteoinductive effect on bone tissue cells, analgesic and anti-inflammatory effects. 1 cl, 1 tbl, 1 ex

Inventors

• Stepanov Aleksandr Gennadevich
• Apresian Samvel Vladislavovich
• Alikov Mirza Khadzhismelovich
• Iudin Leonid Pavlovich

Dates

Publication Date

20260505

Application Date

20250414

Claims (1)

1. A method for stimulating reparative osteogenesis of jaw bones during dental implantation, including the use of chondroitin sulfate, wherein the day before dental implantation, the patient is administered 100 mg of chondroitin sulfate intramuscularly, during the operation, osteoplastic material impregnated with a solution of chondroitin sulfate is introduced into the intraoperative defect, in the postoperative period, the drug chondroitin sulfate is administered intramuscularly according to the following scheme: starting from the day of the operation, 3 injections of 100 mg of chondroitin sulfate per day, on the fourth day and then 12 injections every other day of 200 mg of chondroitin sulfate.

Description

The invention relates to the field of medicine, namely to surgical dentistry, and can be used for osseointegration of dental implants in patients with mineral metabolism disorders in the jaw bones. Bone tissue regeneration during reconstructive procedures in dental implantology is a pressing issue. Restoring bone loss through physiological regeneration is not always possible to the desired extent, for example, due to mineral metabolism disorders, especially in the elderly, which slow down reparative osteogenesis of the jawbone. Furthermore, localized bone loss at the implant site hinders its placement, and reduced mineral density reduces osseointegration. Chondroitin sulfate is currently used as an effective treatment for bone regeneration. This drug has already proven effective in the treatment of osteoarthritis of the peripheral joints and spine by normalizing metabolism in hyaline tissue and stimulating articular cartilage regeneration. Chondroitin sulfate regulates bone and cartilage metabolism and has a chondroprotective and chondrostimulating effect. It stimulates regeneration, improves phosphorus-calcium metabolism in cartilage, inhibits enzymes that disrupt the structure and function of articular cartilage, and slows cartilage degeneration. Chondroitin sulfate also slows bone resorption, reduces calcium loss, and accelerates bone repair processes. In the field of guided tissue regeneration, an invention known under Russian Patent No. 2367475 is used. This invention utilizes a membrane made of non-demineralized or demineralized type I collagen obtained from spongy bone tissue, saturated with sulfated glycosaminoglycans heparin and chondroitin sulfate. According to this invention, the membrane is applied to bone defects. As the authors note, the use of this membrane for targeted tissue regeneration allows for a more predictable clinical effect in the restoration of hard and soft tissues in various pathological conditions, reduces the incidence of complications, and improves surgical outcomes by reducing antigenicity and increasing biocompatibility when using bone collagen saturated with a mixture of heparin and chondroitin sulfate as the membrane material. In the field of dental implantation, according to Russian Patent No. 2367475, a membrane is placed on the alveolar ridge, with one or more openings made in the membrane, depending on the number of implants being installed. These openings allow for the placement of the implants. According to the authors of this invention, this prevents connective tissue ingrowth between the implant and the bone plate, and also elevates the alveolar ridge by 1.5-2.0 mm. The disadvantages of this solution in the field of dental implantation include the lack of effectiveness of the method, since the result is based only on isolating the ingrowth of connective tissue into the free space between the implant and bone tissue; there is no improvement in the process of osseointegration between the implant and bone tissue (alveolar and basal bone). In accordance with the present invention, the prior art discloses Russian Federation Patent No. 2509554, which discloses a solution for producing coatings on implants and biomaterials, containing a solution of a viscous biopolymer and chondroitin sulfate, wherein the viscous biopolymer is hyaluronic acid mixed with chondroitin sulfate and heparin in a sodium chloride solution in the following ratio of components, mass %: hyaluronic acid 1.0-4.0; chondroitin sulfate 1.0-4.0; heparin 0.1-0.5; sodium chloride 0.85-0.9. The implant coating, according to Russian patent No. 2509554, is a viscous solution with the property of prolonged release of components. The disadvantages of this solution include the low efficacy of the active ingredients due to their prolonged release. Thus, only a small portion of the components are available at any given time. A slowly resorbable coating releases the active ingredients as they dissolve. This coating also limits the penetration of the active ingredients into bone tissue, as the surface area of interaction is limited by the coating itself. Furthermore, the amount of active ingredients is relatively small, as the volume of coating that can be applied to the implant and injected into the dental defect is severely limited. The shortcomings of both technical solutions also include the short-term effect of chondroitin sulfate, since the half-life of the drug when administered locally is 2.5 hours; after two days, its amount, even with prolonged release, tends to zero. From the Russian Federation patent No. 2667468, a method is known for treating injuries of the musculoskeletal system associated with a violation of the integrity of the bone, by stimulating the formation of bone callus, including the injection of chondroitin sulfate intramuscularly, wherein chondroitin sulfate is administered in a total course of 10-14 injections, wherein the 1st injection of chondroitin sulfate is carried out as soon as pos